Filtered By:
Specialty: Drugs & Pharmacology
Condition: Alcoholism

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 60 results found since Jan 2013.

(-)- α-Bisabolol prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice.
(-)-α-Bisabolol prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice. Eur J Pharmacol. 2018 Oct 01;: Authors: Fernandes MYD, Santos do Carmo MR, Fonteles AA, de Sousa Neves JC, da Silva ATA, Pereira JF, de Oliveira Ferreira E, de Lima NMR, Neves KRT, de Andrade GM Abstract The pathophysiology of ischemic stroke involves multiple events such as inflammation and oxidative stress which will lead to neuronal death and cognitive deficits. The (-)-α-bisabolol is a monocyclic sesquiterpene alcohol found in various pla...
Source: European Journal of Pharmacology - October 1, 2018 Category: Drugs & Pharmacology Authors: Fernandes MYD, Santos do Carmo MR, Fonteles AA, de Sousa Neves JC, da Silva ATA, Pereira JF, de Oliveira Ferreira E, de Lima NMR, Neves KRT, de Andrade GM Tags: Eur J Pharmacol Source Type: research

Chymase inhibitor prevents the development and progression of  non-alcoholic steatohepatitis in rats fed a high-fat and high-cholesterol diet
Publication date: Available online 20 June 2017 Source:Journal of Pharmacological Sciences Author(s): Yuta Miyaoka, Denan Jin, Keitaro Tashiro, Koji Komeda, Shinsuke Masubuchi, Fumitoshi Hirokawa, Michihiro Hayashi, Shinji Takai, Kazuhisa Uchiyama The effect of the chymase inhibitor TY-51469 on the development and progression of non-alcoholic steatohepatitis (NASH) was evaluated in rats fed a high-fat and high-cholesterol (HFC) diet. To evaluate the preventive effect of TY-51469 on the development of NASH, stroke-prone spontaneously hypertensive rat 5 (SHRSP5)/Dmcr rats were fed either a normal or HFC diet for 8 weeks, an...
Source: Journal of Pharmacological Sciences - July 1, 2017 Category: Drugs & Pharmacology Source Type: research

Chymase inhibitor prevents the development and progression of non-alcoholic steatohepatitis in rats fed a high-fat and high-cholesterol diet
Publication date: Available online 20 June 2017 Source:Journal of Pharmacological Sciences Author(s): Yuta Miyaoka, Denan Jin, Keitaro Tashiro, Koji Komeda, Shinsuke Masubuchi, Fumitoshi Hirokawa, Michihiro Hayashi, Shinji Takai, Kazuhisa Uchiyama The effect of the chymase inhibitor TY-51469 on the development and progression of non-alcoholic steatohepatitis (NASH) was evaluated in rats fed a high-fat and high-cholesterol (HFC) diet. To evaluate the preventive effect of TY-51469 on the development of NASH, stroke-prone spontaneously hypertensive rat 5 (SHRSP5)/Dmcr rats were fed either a normal or HFC diet for 8 weeks, an...
Source: Journal of Pharmacological Sciences - June 20, 2017 Category: Drugs & Pharmacology Source Type: research

Markers of early vascular ageing.
CONCLUSIONS: Vascular measurements may better represent the continuum of cardiovascular disease from a young healthy to an aged diseased vessel that is going to produce adverse clinical events. PMID: 28356037 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - March 28, 2017 Category: Drugs & Pharmacology Authors: Kotsis V, Antza C, Doundoulakis I, Stabouli S Tags: Curr Pharm Des Source Type: research

The Neuroprotective Effect of Rosemary (Rosmarinus Officinalis L. ...
The prevention of BBB breakdown and the subsequent vasogenic edema are important parts of the medical management of ischemic stroke. The purpose of this study was to investigate the ischemic tolerance effect of Rosmarinus officinalis leaf hydro-alcoholic extract (RHE).Five groups of animals were designed: sham (underwent surgery without MCAO) and MCAO groups, the MCAO groups were pretreated orally by gavages with RHE (50, 75, and 100 mg/kg/day), daily for 30 days. Two hours after the last dose, serum lipid levels were determined and then the rats were subjected to 60 min of middle cerebral artery occlusion followed by 24 h...
Source: Iranian Journal of Pharmaceutical Research - November 14, 2016 Category: Drugs & Pharmacology Source Type: research

Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis
Conclusions Rivaroxaban is a valuable treatment option for patients with biological prostheses, repaired mitral valves, or a tubular aortic graft in order to prevent thromboembolic complications.
Source: Clinical Drug Investigation - July 10, 2016 Category: Drugs & Pharmacology Source Type: research

Association of High Homocysteine Levels With the Risk Stratification in Hypertensive Patients at Risk of Stroke.
Abstract PURPOSE: We aimed to investigate the association between stroke morbidity and different stratifications of classic risk factors, such as increasing age, body mass index (BMI), blood lipids, and blood glucose, in hypertensive patients with high homocysteine levels. METHODS: A cross-sectional study of 2258 patients with primary hypertension were enrolled in this study, including 871 stroke cases (62.89%) in 1385 hypertensive patients without hyperhomocysteinemia (HHcy) and 647 (74.11%) stroke cases in 873 hypertensive patients with HHcy. Basic information of patients were collected, including age, sex,...
Source: Clinical Therapeutics - March 23, 2016 Category: Drugs & Pharmacology Authors: Pang H, Han B, Fu Q, Zong Z Tags: Clin Ther Source Type: research

Pharmacological Prophylaxis for Venous Thromboembolism Among Hospitalized Patients With Acute Medical Illness: An Electronic Medical Records Study
The objectives of this study were to examine pharmacological prophylaxis against VTE among hospitalized medically ill patients and to assess demographic and clinical correlates related to VTE prophylaxis. A retrospective (1999–2010) electronic medical records study included patients aged 40 years and older hospitalized for at least 3 days, with significant medical illness or with a VTE hospitalization 30–365 days before admission. Each patient's first qualifying hospitalization was analyzed. Exclusions were if VTE treatment was started within 1 day of admission, or if warfarin (and not heparin or enoxaparin) was used. ...
Source: American Journal of Therapeutics - March 1, 2016 Category: Drugs & Pharmacology Tags: Original Articles Source Type: research

Predictors of Gastrointestinal Bleeding Among Patients with Atrial Fibrillation After Initiating Dabigatran Therapy
ConclusionThe risk of GI bleeding in patients receiving dabigatran is highly associated with increased age and cardiovascular, renal, and other comorbidities, even after adjusting for other factors. Fewer than 50% of patients restarted an anticoagulant after experiencing a GI bleed. Clinicians should continue to monitor for these risk factors or consider whether alternative therapies may be appropriate.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 1, 2015 Category: Drugs & Pharmacology Authors: Julie C. Lauffenburger, Denise H. Rhoney, Joel F. Farley, Anil K. Gehi, Gang Fang Tags: Original Research Article Source Type: research

Alteration of glutamate/GABA balance during acute alcohol intoxication in rats: Effect of Xingnaojing injection
Conclusions The current changes in glutamate, GABA and mRNA expressions of related receptors in LHA after injection of XNJI suggest that changes in these neurotransmitters and receptors as a potential mechanism of action for AAI. Graphical abstract
Source: Journal of Ethnopharmacology - April 5, 2015 Category: Drugs & Pharmacology Source Type: research

Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?
Abstract Atrial fibrillation (AF) confers a 4.5% risk of stroke per year. The risk of stroke increases with various risk factors and until recently, warfarin has been the gold standard of thromboembolism prophylaxis in AF for many years. The dosage of warfarin requires regular adjustment dependent on the INR, to keep within a narrow therapeutic range of 2.0- 3.0. The INR can be altered by concomitant drugs, foods and alcohol and requires inconvenient blood monitoring. Underanticoagulation places patients at risk of stroke, whilst over-anticoagulation confers significant bleeding risk. Consequently approximately ha...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Foley J, Kirchhof P, Lip GY Tags: Curr Vasc Pharmacol Source Type: research

Bleeding as an Outcome Among Patients With Nonvalvular Atrial Fibrillation in a Large Managed Care Population.
CONCLUSIONS: Bleeding incidence among patients with NVAF in a real-world setting was high and increased with greater stroke and bleeding risk scores. Health care costs for patients with major bleeding events were elevated. All rights reserved. PMID: 24075151 [PubMed - as supplied by publisher]
Source: Clinical Therapeutics - September 25, 2013 Category: Drugs & Pharmacology Authors: Deitelzweig SB, Pinsky B, Buysman E, Lacey M, Makenbaeva D, Wiederkehr D, Graham J Tags: Clin Ther Source Type: research

The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: an Update.
Abstract The prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide. T2DM is associated with both microvascular (neuropathy, nephropathy and retinopathy) and macrovascular complications [coronary artery disease (CAD), stroke, carotid artery disease and peripheral artery disease (PAD)]. Apart from acting on diabetic dyslipidemia, statins were shown to exert beneficial effects on several diabetic complications as well as other cardiovascular (CVD) risk predictors such as endothelial dysfunction, inflammation, oxidative stress, chronic kidney disease (CKD), non-alcoholic fatty liver disease (NAFLD), me...
Source: Current Pharmaceutical Design - September 12, 2013 Category: Drugs & Pharmacology Authors: Niki Katsiki, Vasilios G Athyros, Asterios Karagiannis, Dimitri P Mikhailidis Tags: Curr Pharm Des Source Type: research

Acute ischemic cerebrovascular events on antiplatelet therapy: What is the optimal prevention strategy?
Abstract Even though patients who develop ischemic stroke despite taking antiplatelet drugs represent a considerable proportion of stroke hospital admissions, there is a paucity of data from investigational studies regarding the most suitable therapeutic intervention. There have been no clinical trials to test whether increasing the dose or switching antiplatelet agents reduces the risk for subsequent events. Certain issues have to be considered in patients managed for a first or recurrent stroke while receiving antiplatelet agents. Therapeutic failure may be due to either poor adherence to treatment, associated c...
Source: Current Pharmaceutical Design - December 26, 2012 Category: Drugs & Pharmacology Authors: Milionis H, Michel P Tags: Curr Pharm Des Source Type: research